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matrices based on hyaluronic acid or derivatives of this molecules, 
such as Hyaff®, mimic the embryonic hyluronic acid-rich environment 
and when used as a delivery vehicle for cell-based therapies in adult 
organisms, promote a recapitulation of these embryonic events. 
This results in the activation of anabolic factors which induce the 
EJGGFSFOUJBUJPO PG UIF DFMMT XJUI UIF ¾OBM BJN PG GBDJMJUBUJOH UJTTVF
repair. The ability of the hyaluronan-based scaffold to reduce also 
the expression and production of molecules involved in cartilage 
degenerative diseases indicates its possible use to treat early lesions 
in osteoarthritic patients. But the problem have to be analyzed 
also from the clinical point of view. Few clinical studies present 
the results of autologous chondrocyte transplantation utilize in 
large degenerative osteoarthritis cartilage lesions.33,34 Although 
Minas33 reports 90% of patients satisfaction after treatment of 
large osteoarthritis lesions, the failure rate in this patient group in 
higher respect to focal lesions (17% and 10% respectively) and 55% 
of failures occurred in osteoarthritis group. Our experience in very 
similar: although we found high rate of clinical improvement, the 
outcome of patients affected by osteoarthritis is lower respect to 
the focal lesions and most of failures are concentrated in this group. 
5IFJNQPSUBOU¾OEJOHPGPVSTUVEZ JTUIBUUJTTVFSFHFOFSBUJPOXBT
found even when implants were placed in joints that had already 
QSPHSFTTFEUPPTUFPBSUISJUJT5IJT¾OEJOHTDPNCJOFEXJUISFTVMUTPG
in vitro studies can address us to suppose that low clinical success 
of tissue engineered cartilage implants can be connected mostly to 
mechanical problems. The clinical utilize of existing tissue engineered 
grafts in osteoarthritis still presents some unresolved problems. First, 
chondrocyte therapy is suitable for cartilage defects surrounded by 
healthy cartilage. In osteoarthritis, However, an entire compartment 
is damaged: the implant placed in the defect will be surrounded by 
damaged cartilage. The cytokines produced by the chondrocytes 
around the implant might cause dedifferentiation or apoptosis of the 
implanted cells. Also the absence of healthy cartilage shoulder can 
lead to the mechanical damage or mobilization of the implant. Some 
authors reports good clinical results of combination of autologous 
chondrocyte implantation with autologous osteochondral plugs.34 
Another important issue is represented by mechanical overloading 
of affected knee compartment even in early osteoarthritis. For this 
reason we cannot recommend the utilize of existing autologous 
chondrocyte implants for the treatment of osteoarthritis. For 
our opinion, the tissue engineered cartilage implant based on 
hyaluronic acid scaffold can be promising for the treatment of early 
osteoarthritis, but the mechanical properties of the graft and the 
mechanical e and biochemical environment of the joint have to be 
improved. Actually our group is involved in European Project STEPS 
which aims to solve this issues regarding the possibility to use tissue 
engineered cartilage in the osteoarthritis joint. 
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In spite of the recent interest in assessing treatments for chondral 
defects, efforts have been underway for over 250 years to heal 
articular cartilage with only moderate progress. One must keep in 
mind that articular cartilage is a highly specialized tissue that needs 
an intact structure to perform its biochemical, biomechanical and 
physiological functions. Once the cartilage is damaged, the repair 
process is typically inadequate, leading to loss of joint integrity, 
more cartilage damage and more severe joint disease. Various 
therapies have attempted to improve resurfacing of cartilage defects 
including surgical modulation relying on endogenous cell repair 
(full-thickness curettage, spongialization, subchondral bone drilling, 
subchondral bone plate microfracture, and abrasion arthroplasty), 
grafting procedures (periosteal autografts, osteochondral graft, 
sternal cartilage autograft) and chondrocytes transplantation, 
relying on exogenous cell sources to promote healing.1 So far, no 
single treatment has clearly shown favorable results in all clinical 
situations long-term. However, arthroscopic subchondral bone 
plate microfracture (ASBPM) provides an economic, technically easy 
procedure that provides good repair tissue in many acute chondral 
defects without compromising the ability to subsequently perform 
other surgical techniques. 
Arthroscopic subchondral bone plate microfracture was developed, 
TUVEJFE BOE ¾STU VTFE DMJOJDBMMZ CZ + 3JDIBSE 4UFBENBO .% UP
enhance chondral resurfacing in human patients. In humans the 
procedure typically involves use of an arthroscopic shaver to do a 
rough shave that removes any cartilage remnants, hand-held curettes 
UPBTTVSFSFNPWBMPGUIFDBMDJ¾FEDBSUJMBHFMBZFSBOETVSHJDBMBXMT
to make numerous perforations through the subchondral bone 
plate. The procedure has been used in about 3,000 humans over 
the past 18 years. In a study2 evaluating human patients 7 to 17 
years after microfracture, 80% experienced a decrease in pain and 
JNQSPWFNFOUJOEBJMZMJWJOH4JHOJ¾DBOUJNQSPWFNFOUXBTSFDPSEFE
for the Lysholm function score and the Tegner activity scale. There 
XBTBMTPTJHOJ¾DBOUJNQSPWFNFOUJOUIF4'BOE80."$TDPSFT
These clinical successes have led to experimental work assessing 
the degree of improvement in placebo controlled studies. In 1996 a 
full thickness chondral defect model was developed on the medial 
condyle of horses to assess the improvement seen with ASBPM 
compared to non-ASBPM treated defects.3 The model was carried 
out in the horse to allow the use of routine arthroscopic equipment, 
access to cartilage with similar thickness to that of humans on 
the medial femoral condyle and the ability to subject the horse 
to controlled long-term strenuous exercise as well as this lesion 
being a clinical entity in the athletic horse. The goal of this study 
was to gain better understanding of how ASBPM may augment the 
healing processes using clinical, gross, histologic, and biochemical 
FYBNJOBUJPOT5IJTTUVEZEFNPOTUSBUFEUIBUBTJHOJ¾DBOUJODSFBTFJO
repair tissue was seen in defects treated with ASBPM compared to 
untreated defects and that there was an increase in type II collagen. 
It was surprising that the histologic character of the repair tissue 
was similar when both groups were compared. The character of the 
SFQBJSUJTTVFXBTBNJYUVSFNBJOMZPG¾CSPDBSUJMBHF5IFTFEBUBXFSF
BMTPMBUFSDPO¾SNFEJOFYQFSJNFOUBMNPEFMTJOEPHTBOESBCCJUTBT
well.4,5 The equine study also suggested that many of the events 
that led to differences between the ASBPM and non-ASBPM treated 
EFGFDUTPDDVSSFEQSJPSUPNPOUIT5IJT¾OEJOHMFEUPBGPMMPXVQ
study that evaluated the short-term effects of ASBPM treatment at 
the molecular level assessing tissues at 2 week intervals up to 8 
XFFLT5IJTTUVEZSFDPO¾SNFEBOVQSFHVMBUJPOPGUZQF**DPMMBHFO
with ASBPM when compared to non-ASBPM treated defects as well as 
the increased volume of tissue that histologically was not different. 
During model development it was observed that using a motorized 
shaver for debridement of partial thickness lesions may be retaining 
DBMDJ¾FE DBSUJMBHF -JLFXJTF BSFBTXJUI DBMDJ¾FE DBSUJMBHF SFUBJOFE
JO UIF ¾STU UXP FRVJOF TUVEJFT TVCKFDUJWFMZ IBE QPPS BUUBDINFOU
PG UIF SFQBJS UJTTVF UP TVSSPVOEJOH CPOF PS DBSUJMBHF 5P DPO¾SN
the consequences associated with incomplete debridement of the 
DBMDJ¾FEDBSUJMBHFBOPUIFSDPOUSPMMFETUVEZXBTVOEFSUBLFOXIJDI
TQFDJ¾DBMMZDPNQBSFEUIFQSFTFODFPSBCTFODFPGDBMDJ¾FEDBSUJMBHF
on defect healing with ASBPM, as well as, arthroscopic biopsy on 
long-term repair tissue healing.7 
The results of this study demonstrated a greater volume of repair 
UJTTVFXJUIUIFSFNPWBMPGDBMDJ¾FEDBSUJMBHF"TJHOJ¾DBOUOFHBUJWF
DPSSFMBUJPO UP QSFTFODF PG DBMDJ¾FE DBSUJMBHF BOE SFQBJS UJTTVF
attachment was also observed. No long-term adverse effects were 
noted with the arthroscopic biopsy of defects. Similar to other 
TUVEJFTOPTJHOJ¾DBOUEJGGFSFODFJOIJTUPMPHJDSFQBJSUJTTVFDIBSBDUFS
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was noted between the treatment groups. It was concluded that the 
SFNPWBMPGUIFDBMDJ¾FEDBSUJMBHFMBZFSBQQFBSTUPQSPWJEFBOPQUJNBM
amount and attachment of repair tissue and that close arthroscopic 
visualization is recommended for debridement of clinical lesions 
UP FOTVSF DPNQMFUF SFNPWBM PG UIF DBMDJ¾FE DBSUJMBHF MBZFS8IJMF
JU IBT CFFO TIPXO UIBU "4#1. IBT B TJHOJ¾DBOU CFOF¾DJBM FGGFDU
on improving repair tissue volume and type II collagen content of 
chondral defects, improvement in the character of the repair tissue 
especially as it relates to biochemical and histologic nature is still an 
objective. In fact most of the recent work with ASBPM has focused on 
methods to make such improvements. Aimed at such improvement 
and based on the major role that both insulin-like growth factor-1 
(IGF-1) and interleukin-1 receptor antagonist (IL-1Ra) play in anabolic 
NFUBCPMJTN PG BSUJDVMBS DBSUJMBHF BOE BOUJJO¿BNNBUPSZ DPOUSPM PG
diseased joints respectively, these molecules were the focus of recent 
"4#1.TUVEJFT#SJF¿ZBOJOWJUSPFYQFSJNFOUBMTUVEZDPNCJOFEUIFTF
UXPNPMFDVMFTUPEFNPOTUSBUFBTJHOJ¾DBOUJODSFBTFJOSFTUPSBUJPO
of proteoglycan content in IL-1 depleted cartilage.8 Based on these 
positive data an in vivo study was carried out in horses.9 To preserve 
UIF CFOF¾UT PG UIF PWFSBMM "4#1. QSPDFEVSF UIF BSUISPTDPQJD
template and ease of ASBPM, these two molecules were delivered to 
the joint using a single intraarticular injection containing adenoviral 
vectors with equine IGF-1 and IL-1Ra as transgenes. This effectively 
allowed these two molecules to be simultaneously produced by 
the synoviocytes within the joint. The results of this study were 
successful in further increasing Type II collagen content as well as 
JNQSPWJOH UIF DPODFOUSBUJPO PG QSPUFPHMZDBO TJHOJ¾DBOUMZ JO UIF
repair tissues exposed to IGF-1/IL-1Ra. Furthermore, there were no 
detrimental effects seen with this augmentation of ASBPM alone. 
Others have also assessed the ability to augment the character of 
repair tissue following ASBPM although to date these methods have 
been performed using arthrotomy incisions. 
Breinan et al. reported on a canine model of cartilage healing 
where ASBPM was augmented with a type II collagen matrix.4 This 
technique dictated the use of an open incision as well as suturing 
the collagen matrix to the surrounding articular cartilage. The results 
PG UIJT TUVEZ EJE OPU EFNPOTUSBUF BOZ TJHOJ¾DBOU JNQSPWFNFOU JO
UJTTVFDIBSBDUFSBCPWFUIF¾CSPDBSUJMBHFOPVTSFQBJSUJTTVFOPSNBMMZ
observed subsequent to ASBPM alone. Dorotka et. al. assessed the 
treatment of experimental ovine cartilage defects with ASBPM alone, 
ASBPM with a 3-D collagen matrix as well as ASBPM with the 3-D 
matrix containing autologous chondrocytes.10 Delivery of the matrix 
BHBJONBOEBUFEBOBSUISPUPNZJODJTJPOBOE¾YBUJPOVTJOHTVUVSFTUP
the surrounding articular cartilage. The group treated with matrix plus 
chondrocytes was observed to have repair tissue having the greatest 
hyaline-like component although evidence of statistical comparisons 
to ASBPM alone was not made. Based on subjective scores there 
was improvement in the O’Driscoll score when ASBPM plus matrix 
alone was compared to matrix with chondrocytes, however, neither 
PGUIFTFHSPVQTXFSFTJHOJ¾DBOUMZCFUUFSUIBO"4#1.BMPOF5IVT
UIFBEEJUJPOPGNBUSJYDPOUBJOJOHDIPOESPDZUFTEJEOPUEF¾OJUJWFMZ
show improvement to ASBPM alone. To assess if a more stable clot 
at the time of debridement would improve healing after ASBPM 
Hoemann et. al. also used an ovine experimental model.11 All 
defects were subjected to ASBPM, the control limb received no 
GVSUIFSUSFBUNFOUXIJMFUIFUSFBUFEMJNCIBEUIFEFGFDU¾MMFEVTJOHB
mixture of chitosan-glycerol and autologous blood, which was then 
allowed to clot in the defects. While the authors elected to perform 
an open incision all described procedures would theoretically be 
QPTTJCMFBSUISPTDPQJDBMMZ'PVSBOJNBMTXFSFTBDSJ¾DFEJNNFEJBUFMZ
post-operatively to assess if more clot was retained with chitosan-
glycerol/blood treatment. While numerically the chitosan-glycerol/
blood treated defects had greater coverage the comparison to 
ASBPM alone was not reported to be statistically different. The gross 
and histologic results of this study were encouraging with treated 
defects showing greater repair tissue with a more hyaline-like 
nature. Furthermore, two of the six ICRS histologic grading criteria 
	TNPPUIOFTTBOEDFMMPSHBOJ[BUJPO
XFSF TJHOJ¾DBOUMZ JNQSPWFE JO
the chitosan-glycerol/blood compared to untreated defects (ASBPM 
alone). It should be noted this was a short-term study of four months 
duration and only four of fourteen condylar defects did not develop 
subchondral bone cysts by the termination of the study. The results 
of this study support further work to assess long-term outcomes as 
XFMMBTUIFQPUFOUJBMGPSPUIFSNFUIPETPGEFGFDU¾MMJOHBUUIFUJNFPG
surgery plus or minus a cellular component to improve repair tissue 
quality. Based on the ability of bone morphogenetic protein 7 (BMP-
7) to induce chondrogenesis Kuo et. al conducted an experimental 
study in juvenile rabbits to assess the ability of BMP-7 to improve 
the repair tissue following ASBPM.5 While the surgical technique did 
not use awls commercially produced for microfracture the addition 
PG #.1 JNQSFHOBUFE JO B UZQF * DPMMBHFO TQPOHF TJHOJ¾DBOUMZ
increased the repair tissue matrix and cellular organization based 
on ICRS histologic outcome parameters. The addition of BMP-7 
JNQSFHOBUFEJOBUZQF*DPMMBHFOTQPOHFTJHOJ¾DBOUMZJODSFBTFEUIF
repair tissue matrix and cellular organization based on ICRS histologic 
outcome parameters. It is important to note this study was carried 
out in young rabbits for a short duration but was well controlled. 
"MTPOPUFXPSUIZXBTUIFGBDUUIFDPMMBHFOTQPOHFXBTQSFTT¾UUFE
into one microfracture hole which could lend its self to arthroscopic 
application. While defects treated with BMP-7 and ASBPM were 
OPU DPNQMFUFMZ ¾MMFEXJUI SFQBJS UJTTVF OPS EJE UIFZ IBWF OPSNBM
hyaline tissue, the results clearly support this treatment modality 
being tested in a large animal model with long-term follow-up. The 
routine use of ASBPM in both human and veterinary practice is wide 
spread and remains the treatment of choice for resurfacing acute 
chondral defects by many surgeons. It is well realized that the repair 
tissue obtained subsequent to this procedure is characterized by 
¾CSPDBSUJMBHFCVUBQQFBSTUPCFGVODUJPOBMMPOHUFSNJONBOZDBTFT
Even with this already successful procedure the medical community 
strives for enhancement of this procedure to gain a more hyaline 
repair tissue with characteristics closer to native articular cartilage. 
Since the focused experimental work began in 1996 it appears that 
altering the joint environment through the use of anabolic and anti-
JO¿BNNBUPSZNPMFDVMFTBTXFMMBTBVHNFOUJOHUIFEFGFDUCFEXJUI
an arthroscopically delivered cellular matrix may be the next step 
beyond microfracture… 
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